5 results about "Squamous cancer" patented technology

The present application provides the use of liposome mitoxantrone hydrochloride in the preparation of a medicament for treating ovarian cancer, gastric cancer or head and neck squamous cancer, a method for treating ovarian cancer, gastric cancer or head and neck squamous cancer by using liposome mitoxantrone hydrochloride preparation, and a liposome mitoxantrone hydrochloride preparation for treating ovarian cancer, gastric cancer or head and neck squamous cancer.

Applicant provides herein methods for treating a patient having a pre-cancerous oral leukoplakia (LK) lesion or for delaying the progression of a pre-cancerous oral LK to oral squamous cell carcinoma. It also provides methods to identify patients that more likely to respond to a therapy comprising administration of an effective amount of an anti-PD-1 or anti-PD-L 1 therapy.

The present application belongs to the technical field of slice image recognition, and particularly relates to a cervical cell pathological slice recognition method based on multi-modal learning, which comprises the following steps: acquiring cervical pathological slice images and clinical text data of a patient, extracting image modal feature vectors and text modal feature vectors through an image encoder and a text encoder respectively; inputting the two modal features into a cross-modal fusion network constructed based on an asymmetric attention mechanism, guiding image feature enhancement with the text feature as a query, guiding text feature enhancement with the image feature as a query, and fusing to generate multi-modal joint feature representation; and outputting classification results such as normal cells, low-grade lesions, high-grade lesions or squamous cell carcinoma based on the joint feature representation. Through bidirectional cross-modal attention interaction, the present application realizes effective fusion of pathological image morphological features and clinical text information, and makes up for the limitations of single-modal data.

The present disclosure relates to the treatment of solid cancers, such as breast cancer, colon cancer, and lung cancer (particularly non-small cell lung cancer (NSCLC)), in human subjects using anti-PD-1 antibodies as monotherapy or as combination therapy with, for example, chemotherapy and / or surgery. The treatments provided may be a combination of tiralizumab and chemotherapy prior to surgery, using different doses of tiralizumab in an auxiliary stage after surgery. Administration regimens may include administration of 200 mg of an anti-PD-1 antibody (e.g., tiralizumab) (e.g., every three weeks) followed by tumor resection, followed by administration of 400 mg of the anti-PD-1 antibody (e.g., every six weeks). Furthermore, the chemotherapy may be platinum-based (e.g., carboplatin and / or cis-platinum), and may further include pemetrexed (e.g., for non-squamous cancer) or paclitaxel (e.g., for squamous cancer).